These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19803013)

  • 1. Ceftazidime: summary of the first international symposium.
    Young LS
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():349-52. PubMed ID: 19803013
    [No Abstract]   [Full Text] [Related]  

  • 2. Why ceftazidime?
    Muggleton PW
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():1-3. PubMed ID: 19810166
    [No Abstract]   [Full Text] [Related]  

  • 3. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.
    Hoepelman AI; Kieft H; Aoun M; Kosmidis J; Strand T; Verhoef J; Gillespie SH; Riddell J; Varghese G; Meunier F
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():175-86. PubMed ID: 8150761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime (Fortaz).
    Med Lett Drugs Ther; 1985 Oct; 27(698):85-7. PubMed ID: 3900663
    [No Abstract]   [Full Text] [Related]  

  • 5. Cefditoren versus ceftazidime in inducer-substrate combinations for the evaluation of AmpC production in a disc approximation test.
    Cafini F; Aguilar L; Alou L; Giménez MJ; Sevillano D; Torrico M; González N; Coronel P; Prieto J
    Rev Esp Quimioter; 2010 Jun; 23(2):72-5. PubMed ID: 20559604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of ceftazidime in severe Gram-negative infections--a preliminary study.
    Clumeck N; Vanlaethem Y; Gordts B; Jaspar N; Butzler JP
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():317-21. PubMed ID: 19803007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftazidime: comparative in-vitro study.
    Verbist L; Verhaegen J
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():67-71. PubMed ID: 19802971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reevaluation of current antimicrobials. Ceftazidime].
    Urabe A; Inamatsu T
    Jpn J Antibiot; 1994 Aug; 47(8):983-90. PubMed ID: 7523743
    [No Abstract]   [Full Text] [Related]  

  • 9. The in-vitro activity of ceftazidime against clinically important pathogens.
    Knothe H; Dette GA
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():33-41. PubMed ID: 19810167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.
    Farfour E; Trochu E; Devin C; Cardot Martin E; Limousin L; Roux A; Picard C; Jolly E; Vasse M; Lesprit P
    Transpl Infect Dis; 2018 Oct; 20(5):e12955. PubMed ID: 29896802
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ceftazidime: review of the microbiological and clinical experience].
    Arosio E; Pancera P; Montesi G
    Recenti Prog Med; 1985 Dec; 76(12):635-42. PubMed ID: 3914016
    [No Abstract]   [Full Text] [Related]  

  • 12. Carumonam versus ceftazidime: in vitro activity, pharmacokinetics in elderly patients, safety and therapeutic efficacy in the treatment of complicated urinary tract infections.
    Naber K; Kees F; Denk K; Bauernfeind A; Grobecker H
    Chemioterapia; 1987 Jun; 6(2 Suppl):517-8. PubMed ID: 3334613
    [No Abstract]   [Full Text] [Related]  

  • 13. What is inadequate antibacterial therapy?
    Moellering RC
    Clin Infect Dis; 2009 Oct; 49(7):1006-8. PubMed ID: 19719418
    [No Abstract]   [Full Text] [Related]  

  • 14. The microbiological assay of ceftazidime.
    Thornton JE
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():225-6. PubMed ID: 19802989
    [No Abstract]   [Full Text] [Related]  

  • 15. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Brogden RN
    Drugs; 1985 Feb; 29(2):105-61. PubMed ID: 3884319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteriological investigations with ceftazidime in vitro.
    Grimm H
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():213-6. PubMed ID: 19802986
    [No Abstract]   [Full Text] [Related]  

  • 17. Ceftazidime regression studies.
    Crosse R; Burt DG; Gardner MJ
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():221-3. PubMed ID: 19802988
    [No Abstract]   [Full Text] [Related]  

  • 18. Doripenem: an early look at a carbapenem not yet approved for pediatrics.
    Overturf GD
    Pediatr Infect Dis J; 2010 Feb; 29(2):163-5. PubMed ID: 20135831
    [No Abstract]   [Full Text] [Related]  

  • 19. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
    Acred P; Ryan DM; Sowa MA; Watts CM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiresistance and 'superbugs'.
    Livermore D
    Commun Dis Public Health; 1998 Jun; 1(2):74-6. PubMed ID: 9644116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.